Cargando…
Review: Effects of anti‐CD38 monoclonal antibodies on red blood cell transfusion and interventions
BACKGROUND: Highly expressed in almost all myeloma cells, CD38 is an attractive treatment target. AIM: Anti‐CD38 monoclonal antibodies have been approved for first‐line treatment in non‐transplantable multiple myeloma (MM) patients. MATERIALS AND METHODS: However, it has been found in clinical use t...
Autores principales: | Song, Jia, Fu, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649382/ https://www.ncbi.nlm.nih.gov/pubmed/34752645 http://dx.doi.org/10.1002/jcla.23832 |
Ejemplares similares
-
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
por: Lancman, Guido, et al.
Publicado: (2018) -
Transfusion management for patients taking an anti-CD38 monoclonal antibody
por: Bub, Carolina Bonet, et al.
Publicado: (2018) -
Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022) -
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020) -
Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping
por: Chami, Btissam, et al.
Publicado: (2022)